2/24/2014

A study in the Journal of Retinal and Vitreous Diseases found that intravitreal administration of ranibizumab did not show significant impact on retinal vessel diameter among diabetic macular edema patients. Researchers also found that reductions in central foveal thickness following ranibizumab treatment were not associated with altered retinal vessel diameter or dilatatory response in patients.

Related Summaries